Showing results (341-350 of 372) with videos related to

Sort By:
Pageof 38
Current Medical Research and Opinion|July 7, 2021
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE studyHiroya Taniguchi, Takayuki Yoshino, Kensei Yamaguchi, et al.
Anti-Cancer Agents in Medicinal Chemistry|January 23, 2025
Chlorogenic Acid Ameliorates CCl4-induced Liver Fibrosis by Modulating the PI3K/AKT/mTOR Autophagy PathwayAmr Negm, Amira A El-Neanaey, Abada El Sayed Khadr, et al.
Blood|February 16, 2023
Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitorEliana B Gomez, Kevin Ebata, Hetal S Randeria, et al.
British Journal of Cancer|May 30, 2018
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH studyIan Chau, Joon Oh Park, Baek-Yeol Ryoo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 26, 2021
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiologyPeter R Galle, Masatoshi Kudo, Josep M Llovet, et al.
Human Molecular Genetics|May 1, 1997
Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 familiesG Cancel, A Dürr, O Didierjean, et al.
The Lancet. Oncology|June 23, 2015
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialAndrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, et al.
Brain : a Journal of Neurology|June 4, 2009
Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystoniaFabienne Clot, David Grabli, Cécile Cazeneuve, et al.
Journal of Gastroenterology|August 24, 2016
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trialMasatoshi Kudo, Etsuro Hatano, Shinichi Ohkawa, et al.
British Journal of Cancer|February 3, 2021
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumabAndrew X Zhu, Richard S Finn, Yoon-Koo Kang, et al.
Pageof 38